Nanomedicine safety focus on infusion reactions

0

Injection/infusion reactions to nanopharmaceuticals (and particulate drug carriers) are idiosyncratic and well documented” Moghimi (2017).

Abstract:

Injection/infusion reactions to nanopharmaceuticals (and particulate drug carriers) are idiosyncratic and well documented. The molecular basis of nanoparticle-mediated injection reactions is debatable, with two hypotheses as front-runners.

The first is complement-activation-related ‘pseudoallergy’, where a causal role for nanoparticle-mediated complement activation in injection/infusion reactions is considered. However, the second hypothesis (the rapid phagocytic response hypothesis) states a transitional link from robust clearance of nanoparticles (NPs) from the blood by strategically placed responsive macrophages to adverse hemodynamic and cardiopulmonary reactions, regardless of complement activation. Here, I critically examine and discuss these hypotheses. Current experimentally derived evidence appears to be more in support of the rapid phagocytic response hypothesis than of the pseudoallergy hypothesis.

Abstract:

Moghimi, S.M. (2017) Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discovery Today. November 13th. [epub ahead of print].

doi: 10.1016/j.drudis.2017.11.006.

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.